Latest Watson CEO Brief Rips Motive For FTC Subpoena

Law360, New York (June 4, 2010, 1:27 PM EDT) -- The Federal Trade Commission's bid to force Watson Pharmaceuticals Inc. CEO Paul M. Bisaro to testify in a competition probe into a patent settlement over the narcolepsy treatment Provigil is an extraordinary circumstance that warrants discovery, his lawyers have told a federal judge.

Bisaro's reply brief, lodged Thursday in the U.S. District Court for the District of Columbia, comes as the agency investigates whether a settlement Watson entered into to end Cephalon Inc.'s patent infringement lawsuit hindered the ability of other generics makers to enter into...
To view the full article, register now.